Navigation Links
Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
Date:9/7/2010

CAMBRIDGE, Mass., Sept. 7 /PRNewswire/ -- Idenix Pharmaceuticals, Inc. (Nasdaq: IDIX) announced today that Idenix management will present a corporate overview at the Robert W. Baird Small Cap Healthcare Conference on Tuesday, September 14, 2010 at 9:30 a.m. ET at the St. Regis Hotel, New York City and at the Stifel Nicolaus Healthcare Conference on Thursday, September 16, 2010 at 11:30 a.m. ET at the Four Seasons Hotel, Boston.

The live and archived webcast of the company presentation can be accessed under "Calendar of Events" in the Idenix Investor Center at www.idenix.com.  Please log in approximately 5-10 minutes before the event to ensure a timely connection.  The archived replay will be available on the Idenix website for two weeks following the conference.  

About IdenixIdenix Pharmaceuticals, Inc., headquartered in Cambridge, Massachusetts, is a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases. Idenix's current focus is on the treatment of patients with chronic hepatitis C infection. For further information about Idenix, please refer to http://www.idenix.com.Idenix Pharmaceuticals Contact:Jonae Barnes (617) 224-4485 (investors)Kelly Barry (617) 995-9033 (media)
'/>"/>

SOURCE Idenix Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Idenix Pharmaceuticals Reports Fourth Quarter and Year End 2009 Financial Results
2. Idenix Pharmaceuticals Successfully Completes Proof-of-Concept Study of IDX184 for the Treatment of Hepatitis C Virus (HCV)
3. Idenix Pharmaceuticals and GlaxoSmithKline Sign Worldwide License Agreement for IDX899, a Novel NNRTI for the Treatment of HIV
4. Idenix Pharmaceuticals Initiates Proof-of-Concept Study of IDX184 for the Treatment of Hepatitis C Virus (HCV)
5. Idenix Pharmaceuticals Announces Completion of Proof-of-Concept Study for IDX899 in Treatment-Naive HIV-Infected Patients
6. Idenix Pharmaceuticals Advances HCV Discovery Program to Clinic
7. Idenix Pharmaceuticals Reports First Quarter 2008 Financial Results
8. Idenix Pharmaceuticals Presents Positive Preclinical Data on HCV Programs at The Annual Meeting of The European Association for the Study of the Liver (EASL)
9. Idenix Pharmaceuticals Provides Update on Hepatitis C Pipeline at JP Morgan Healthcare Conference
10. MAP Pharmaceuticals to Present at Upcoming Healthcare and Scientific Conferences
11. Tibotec Pharmaceuticals Seeks European Marketing Authorization for Investigational Once-Daily HIV Treatment TMC278
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2017)... Research and Markets has announced the addition of the ... Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2014 ... ... US$ 7,167.6 Mn in 2015, and is expected to reach ... 5.6% from 2016 to 2024. The global ...
(Date:4/19/2017)... 2017 Cardiology devices segment is anticipated to reach ... The Cardiology Devices segment is likely to create absolute $ ... 2018 over 2017. By the end of 2027, Cardiology Devices ... US$ 700 Mn, expanding at a CAGR of 18.4% over ... Asia Pacific reprocessed medical devices market in ...
(Date:4/19/2017)... Tenn. and DALLAS , April 19, 2017 ... announced that the first patients in Nashville ... device in the Lower Esophageal Sphincter Stimulation for GERD ... implantable device designed to provide long-term reflux control by ... GERD affects nearly 65 million people in ...
Breaking Medicine Technology:
(Date:4/28/2017)... ... April 28, 2017 , ... ... pilot study of ActiGraph’s CentrePoint Data Hub in a sample of ... of clinical-grade wearable activity and sleep monitoring solutions for the global scientific community. ...
(Date:4/28/2017)... ... April 28, 2017 , ... ... and advanced nutraceutical supplements, through its Nova Skin Sciences division, recently announced the ... of a moisturizer with the power of an anti-aging concentrate. , ...
(Date:4/28/2017)... ... April 28, 2017 , ... Semrock’s highly popular ... premier online modeling resource for fluorescence microscopists and optical system designers, enabling The ... 5 years spanning the globe, SearchLight has become a tremendously popular tool for ...
(Date:4/27/2017)... ... 27, 2017 , ... The Incentive Research Foundation is pleased ... Guide," a groundbreaking analysis of how behavioral economics can be applied to the ... IRR programs, the report highlights proven behavioral economics approaches and the powerful role ...
(Date:4/27/2017)... , ... April 27, 2017 , ... ... husband Dan Gasby the 2017 Public Leadership in Neurology Award (PLINA). The couple ... professional athlete Tedy Bruschi, Vice President Walter Mondale, actor Michael J. Fox and ...
Breaking Medicine News(10 mins):